Treatment options and outcomes of hospitalised tuberculosis patients: a nationwide study

Int J Tuberc Lung Dis. 2015 Jan;19(1):120-6. doi: 10.5588/ijtld.14.0333.

Abstract

Setting: Although standardised multidrug treatments exist, mortality among hospitalised tuberculosis (TB) patients is high.

Objective: To characterise TB patients requiring acute hospital care and identify factors associated with in-hospital mortality.

Design: Using a Japanese national database of acute-care hospitals, we identified patients with sputum smear-positive pulmonary TB who were discharged (both deceased and alive) between July 2010 and March 2013. Demographic characteristics, comorbidity, procedures and treatments were examined. We performed a multivariable logistic regression analysis to identify risk factors for in-hospital mortality.

Results: Of 877 treated patients (566 males, mean age 74.5 years) identified, 152 (17.3%) died. A standard four-drug regimen of isoniazid (INH), rifampicin (RMP), ethambutol (EMB) and pyrazinamide was given to 279 (31.8%) patients, and INH, RMP and EMB to 335 (38.2%) patients. Multivariable analysis showed that the three-drug regimen was significantly associated with higher rates of in-hospital mortality (OR 1.87, 95%CI 1.07-3.27, P = 0.028). Other factors associated with in-hospital death were age, male sex, smoking habit, emergency admission, dementia and severe respiratory condition.

Conclusion: The risk factors for in-hospital death identified include the use of the three-drug regimen. Treatment choice could influence the outcome of hospitalised TB patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antitubercular Agents / therapeutic use
  • Child
  • Child, Preschool
  • Ethambutol / therapeutic use
  • Female
  • Hospital Mortality
  • Hospitalization*
  • Humans
  • Infant
  • Infant, Newborn
  • Isoniazid / therapeutic use
  • Japan / epidemiology
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Patient Discharge
  • Pyrazinamide / therapeutic use
  • Retrospective Studies
  • Rifampin / therapeutic use
  • Risk Factors
  • Sputum / microbiology
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / mortality*
  • Young Adult

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Ethambutol
  • Isoniazid
  • Rifampin